Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.209,44-0,82 %

Gold3.351,860,00 %

Öl (Brent)69,25-0,48 %

Dow Jones44.329,33-0,39 %

US Tech 10023.064,03-0,11 %

EUR/USD1,16385+0,34 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

CytomX Therapeutics Aktie

Aktie

ISIN: US23284F1057 WKN: A14158 SYM: 6C1 Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

2,0520

EUR

-0,19 %

-0,0040 EUR

Letzter Kurs 18.07.25 Tradegate

CytomX Therapeutics Aktie kaufen

Geldkurs

18.07.25

2,0240

EUR

3.956 STK

Briefkurs

18.07.25

2,0820

EUR

3.842 STK

BEI SMARTBROKER+ HANDELN

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Baader Tragding

Neueste Nachrichten

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference 29.05.25 · globenewswire · CytomX Therapeutics
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma 19.05.25 · globenewswire · CytomX Therapeutics
Fokus Aktien mit extremen Handelsvolumen am Montag, den 12.05.2025 12.05.25 · wO Chartvergleich · JDC Group
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock 12.05.25 · globenewswire · CytomX Therapeutics
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) 12.05.25 · globenewswire · CytomX Therapeutics
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update 12.05.25 · globenewswire · CytomX Therapeutics
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 05.05.25 · globenewswire · CytomX Therapeutics
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting 28.04.25 · globenewswire · CytomX Therapeutics
IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape \| DelveInsight 24.04.25 · PR Newswire (engl.) · Daiichi Sankyo
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update 06.03.25 · globenewswire · CytomX Therapeutics
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference 05.03.25 · globenewswire · CytomX Therapeutics
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 27.02.25 · globenewswire · CytomX Therapeutics

1
2

Meistgelesen

12 Monate

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update 572 Leser
Fokus Aktien mit extremen Handelsvolumen am Montag, den 12.05.2025 460 Leser
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024 408 Leser
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update 368 Leser
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update 364 Leser
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b ... 352 Leser
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 324 Leser
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock 304 Leser
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug ... 224 Leser
IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer ... 216 Leser